Oxford BioDynamics (Oxford BioDynamics) EBIT : $-13.75 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Oxford BioDynamics EBIT?

Oxford BioDynamics's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2023 was $-8.09 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-13.75 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Oxford BioDynamics's annualized ROC % for the quarter that ended in Sep. 2023 was -96.23%. Oxford BioDynamics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -181.04%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Oxford BioDynamics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -41.85%.

Oxford BioDynamics EBIT Historical Data

The historical data trend for Oxford BioDynamics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics EBIT Chart

Oxford BioDynamics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBIT

Get a 7-Day Free Trial

-4.19

-6.38

-10.32

-8.35

-13.86

Oxford BioDynamics Semi-Annual Data
	Sep13	Sep14	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EBIT	Get a 7-Day Free Trial														-5.61	-4.15	-4.78	-5.66	-8.09

Competitive Comparison of Oxford BioDynamics's EBIT

For the Biotechnology subindustry, Oxford BioDynamics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioDynamics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioDynamics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's EV-to-EBIT falls into.

Oxford BioDynamics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-13.75 Mil.

Oxford BioDynamics (OTCPK:OXBOF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Oxford BioDynamics's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-13.392 * ( 1 - 4.15% )	/	( (11.506	+	15.171)	/ 2 )
=	-12.836232	/	13.3385
=	-96.23 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	17.333	-	1.43	-	( 4.397	-	max(0, 2.551	-	7.398	+	4.397	))
=	11.506

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19.959	-	0.87	-	( 6.498	-	max(0, 4.952	-	8.87	+	6.498	))
=	15.171

Note: The Operating Income data used here is two times the semi-annual (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Oxford BioDynamics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-16.178	/	( ( (7.868 + max(1.344, 0))	+	(8.66 + max(-2.735, 0)) )	/	2 )
=	-16.178	/	( ( 9.212	+	8.66 )	/	2 )
=	-16.178	/	8.936
=	-181.04 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.549	+	0.453	+	-0.0010000000000003)	-	(1.43	+	0	+	0.227)
=	1.344

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.017	+	0.339	+	0.849)	-	(0.87	+	0	+	3.07)
=	-2.735

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Oxford BioDynamics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-13.747	/	32.849
	=	-41.85 %

Oxford BioDynamics EBIT Related Terms

Thank you for viewing the detailed overview of Oxford BioDynamics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioDynamics (Oxford BioDynamics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (OTCPK:OXBOF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

OBD:UK

Address

Oxford Business Park South, 3140 Rowan Place, John Smith Drive, Oxford, GBR, OX4 2WB

Website

https://www.oxfordbiodynamics.com

Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.